Pharmacology of catamenial epilepsy

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 26, Issue 7, 2004, Pages 547-561

  Reddy, Doodipala S ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

Allopregnanolone; Epilepsy; GABAA receptor; Ganaxolone; Neurosteroid

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 4 AMINOBUTYRIC ACID A RECEPTOR; ACETAZOLAMIDE; ANDROSTANEDIOL; ANTICONVULSIVE AGENT; ANTIGESTAGEN; BENZODIAZEPINE DERIVATIVE; CLOBAZAM; CLOMIFENE; CLONAZEPAM; DEOXYCORTICOSTERONE; DIAZEPAM; ESTRADIOL; ESTRIOL; ESTROGEN; ESTRONE; FOLLITROPIN; GANAXOLONE; HYDROCORTISONE; LUTEINIZING HORMONE; MEDROXYPROGESTERONE ACETATE; MIFEPRISTONE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROSTEROID; PROGESTERONE; PROGESTERONE DERIVATIVE; PROGESTERONE RECEPTOR A; PROGESTERONE RECEPTOR B; TRIPTORELIN; UNINDEXED DRUG;

AMENORRHEA; ANTICONVULSANT ACTIVITY; BRAIN LEVEL; BREAKTHROUGH BLEEDING; BREAST TENDERNESS; CATAMENIAL EPILEPSY; CLINICAL PROTOCOL; CLINICAL TRIAL; DEPRESSION; DRUG CROSS TOLERANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EXPERIMENTAL MODEL; FATIGUE; FOCAL EPILEPSY; GENERALIZED EPILEPSY; HORMONAL REGULATION; HORMONAL THERAPY; HUMAN; INCIDENCE; NERVE CELL PLASTICITY; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SEDATION; SEIZURE SUSCEPTIBILITY; SIDE EFFECT;

ANIMALS; ANTICONVULSANTS; AREA UNDER CURVE; EPILEPSY; ESTROGENS; FEMALE; HALF-LIFE; HUMANS; INCIDENCE; MENSTRUAL CYCLE; MICE; PREGNANOLONE; PROGESTERONE; RECEPTORS, GABA-A;

EID: 8344250988     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2004.26.7.863737     Document Type: Review

References (156)

1. Jacobs, M.P., Fischbach, G.D., Davis, M.R. et al. Future directions for epilepsy research. Neurology 2001, 57: 1536-42.
2. Dickerson, W. Effect of menstruation on seizures. J Nerv Ment Dis 1941, 94: 160-9.
3. Rosciszewska, D. Analysis of seizure dispersion during menstrual cycle in women with epilepsy. Monogr Neural Sci 1980, 5: 280-4.
4. Tauboll, E., Lundervold, A., Gjerstad, L. Temporal distribution of seizures in epilepsy. Epilepsy Res 1991, 8: 153-65.
5. Duncan, S., Read, C.L., Brodie, M.J. How common is catamenial epilepsy? Epilepsia 1993, 34: 827-31.
6. Towanabut, S., Chulavatnatol, S., Suthisisang, C., Wanakamanee, U. The period prevalence of catamenial epilepsy at Prasat Neurological Institute, Bangkok. J Med Assoc Thai 1998, 81: 970-7.
7. Newmark, M.E., Penry, J.K. Catamenial epilepsy: A review. Epilepsia 1980, 21: 281-300.
8. Herzog, A.G., Klein, P., Ransil, B.J. Three patterns of catamenial epilepsy. Epilepsia 1997, 38: 1082-8.
9. Gowers, W.R. Epilepsy and Other Chronic Convulsive Diseases. Their Causes, Symptoms, and Treatment. London: J & A Churchill 1881, 197.
10. Rosciszewska, D., Buntner, B., Guz, I., Zawisza, L. Ovarian hormones, anticonvulsant drugs, and seizures during the menstrual cycle in women with epilepsy. J Neurol Neurosurg Psychiatry 1986, 49: 47-51.
11. McQuarrie, I., Peeler, D.B. The effects of sustained pituitary antidiuresis and forced water drinking in epileptic children. A diagnostic and etiologic study. J Clin Invest 1931, 915-40.
12. Ansell, B., Clarke, E. Acetazolamide in treatment of epilepsy. Brit Med J 1956, 1: 650-61.
13. Shavit, G., Lerman, P., Korczyn, A.D., Kivity, S., Bechar, M., Gitter, S. Phenytoin pharmacokinetics in catamenial epilepsy. Neurology 1984, 34: 959-61.
14. Kumar, N., Behari, M., Ahuja, G.K., Jailkhani, B.L. Phenytoin levels in catamenial epilepsy. Epilepsia 1988, 29: 155-8.
15. Foldvary-Schaefer, N., Falcone, T. Catamenial epilepsy: Pathophysiology, diagnosis, and management. Neurology 2003, 61(Suppl 2): S2-15.
16. Narbone, M.C., Ruello, C., Oliva, A. et al. Hormonal disregulation and catamenial epilepsy. Funct Neurol 1990, 5: 49-53.
17. Herzog, A.G. Reproductive endocrine considerations and hormonal therapy for women with epilepsy. Epilepsia 1991, 32 (Suppl 6): S27-33.
18. Herkes, G.K., Eadie, M.J., Sharbrough, F., Moyer, T. Patterns of seizure occurrence in catamenial epilepsy. Epilepsy Res 1993, 15: 47-52.
19. Rodriguez-Macias, KA. Catamenial epilepsy: Gynecological and hormonal implications. Five case reports. Gynecol Endocrinol 1996, 10: 139-42.
20. Harden, C.L., Pulver, M.C., Ravdin, L., Jacobs, A.R. The effect of menopause and perimenopause on the course of epilepsy. Epilepsia 1999, 40: 1402-7.
21. Joels, M. Steroid hormones and excitability in the mammalian brain. Front Neuroendocrinol 1997, 18: 2-48.
22. Rogawski, M.A., Reddy, D.S. Neurosteroids: Endogenous modulators of excitability. In: Epilepsy: Scientific Foundations of Clinical Treatment. Rho, J.M., Sankar, R., Cavazos, J. (Eds.). Marcel Dekker, 2004, 319-55.
23. A receptor function and seizure susceptibility. J Neurosci 2002, 42: 3795-805.
24. Reddy, D.S. Anticonvulsant activity of the testosterone-derived neurosteroid 3alpha-androstanediol. NeuroReport 2004, 15: 515-8.
25. Logothetis, J., Harner, R. Electrocortical activation by estrogens. Arch Neurol 1960, 3: 290-7.
26. Woolley, D.E., Timiras, P.S. The gonad-brain relationship: Effects of female sex hormones on electroshock convulsions in the rat. Endocrinology 1962, 70: 196-209.
27. Woolley, D.E., Timiras, P.S. Estrous and circadian periodicity and electroshock convulsions in rats. Am J Physiol 1962, 202: 379-82.
28. Werboff, L.H., Havlena, J. Audiogenic seizures in adult male rats treated with various hormones. Gen Comp Endocrinol 1963, 3: 389-97.
29. Teresawa, E., Timiras, P.S. Electrical activity during the estrous cycle of the rat: Cyclic changes in limbic structures. Endocrinology 1968, 83: 207-16.
30. Hom, A.C., Buterbaugh, G.G. Estrogen alters the acquisition of seizures kindled by repeated amygdala stimulation or pentyeletetrazol administration in ovariectomized female rats. Epilepsia 1986, 27: 103-8.
31. Buterbaugh, G.G. Estradiol replacement facilitates the acquisition of seizures kindled from the anterior neocortex in female rats. Epilepsy Res 1989, 4: 207-15.
32. Buterbaugh, G.G., Hudson. G.M. Estradiol replacement to female rats facilitates dorsal hippocampal but not ventral hippocampal kindled seizure acquisition. Exp Neurol 1991, 11: 55-64.
33. Edwards, H.E., Burnham, W.M., Mendonca, A., Bowlby, D.A., MacLusky, N.J. Steroid hormones affect limbic afterdischarge thresholds and kindling rates in adult female rats. Brain Res 1999, 838: 136-50.
34. Nicoletti, F., Speciale, C., Sortino, M.A. et al. Comparative effects of estradiol benzoate, the antiestrogen clomiphene citrate and the progestin medroxyprogesterone acetate on kainic acid-induced seizures in male and female rats. Epilepsia 1985, 26: 252-7.
35. Woolley, C.S. Estradiol facilitates kainic acid-induced, but not flurothyl-induced, behavioral seizure activity in adult female rats. Epilepsia 2000, 41: 510-5.
36. Smith, S.S., Waterhouse, B.D., Woodward, D.J. Locally applied estrogens potentiate glutamate-evoked excitation of cerebellar Purkinje cells. Brain Res 1988, 475: 272-82.
37. Wong, M., Moss, R.L. Patch-clamp analysis of direct steroidal modulation of glutamate receptor-channels. J Neuroendocrinol 1994, 6: 347-55.
38. Murphy, D.D., Cole, N.B., Greenberger, V., Segalm, M. Estradiol increases dendritic spine density by reducing GABA neurotransmission in hippocampal neurons. J Neurosci 1998, 18: 2550-9.
39. Woolley, C.S., Weiland, N.G., McEwen, B.S., Schwartzkroin, P.A. Estradiol increases the sensitivity of hippocampal CA1 pyramidal cells to NMDA receptor-mediated synoptic input: Correlation with dendritic spine density. J Neurosci 1997, 17: 1848-59.
40. Rudick, C.N., Woolley, C.S. Estrogen regulates functional inhibition of hippocampal CA1 pyramidal cells in the adult female rat. J Neurosci 2001, 21: 6532-43.
41. Logothetis, J., Harner, R., Morrel, F. The role of estrogens in catamenial exacerbation of epilepsy. Neurology 1959, 9: 352-60.
42. Bäckström, T. Epileptic seizures in women related to plasma estrogen and progesterone during the menstrual cycle. Acta Neurol Scand 1976, 54: 321-47.
43. Jacono, J.J., Robinson, J. The effects of estrogen, progesterone, and ionized calcium on seizures during the menstrual cycle in epileptic women. Epilepsia 1997, 28: 571-7.
44. Selye, H. The antagonism between anesthetic steroid hormones and pentamethylenetetrazol (metrazol). J Lab Clin Med 1942, 27: 1051-3.
45. Craig, C.R. Anticonvulsant activity of steroids: separability of anticonvulsant from hormonal effects. J Pharmacol Exp Ther 1966, 153: 337-43.
46. Landgren, S., Backstrom, T., Kalistratov, G. The effect of progesterone on the spontaneous interictal spike evoked by the application of penicillin to the cat's cerebral cortex. J Neurol Sci 1978, 36: 119-33.
47. Bäckström, T., Zetterlund, B., Blom, S., Romano, M. Effect of intravenous progesterone infusions on the epileptic discharge, frequency in women with partial epilepsy. Acta Neurol Scand 1984, 69: 240-8.
48. Lonsdale, D., Burnham, W.M. The anticonvulsant effects of progesterone and 5alpha-dihydroprogesterone on amygdala-kindled seizures in rats. Epilepsia 2003, 44: 1494-9.
49. Herzog, A.G. Intermittent progesterone therapy of partial complex seizures in women with menstrual disorders. Neurology 1986, 36: 1607-10.
50. Herzog, A.G. Progesterone therapy in women with complex partial and secondary generalized seizures. Neurology 1995, 45: 1600-62.
51. Herzog, A.G. Progesterone therapy in women with epilepsy: A 3-year follow-up. Neurology 1999, 52: 1917-8.
52. Bonuccelli, U., Melis, G.B., Paoletti, A.M., Fioretti, P., Murri, L., Muratorio, A. Unbalanced progesterone and estradiol secretion in catamenial epilepsy. Epilepsy Res 1989, 3: 100-6.
53. Herzog, A.G., Friedman, M.N., Freund, S., Pascual-Leone, A. Transcranial magnetic stimulation evidence of a potential role for progesterone in the modulation of premenstrual corticocortical inhibition in a woman with catamenial seizure exacerbation. Epilepsy Behav 2001, 2: 367-9.
54. Laidlaw, J. Catamenial epilepsy. Lancet 1956, 271: 1235-7.
55. Voiculescu, V., Hategan, D., Manole, E., Ulmeanu, A. Increased susceptibility to audiogenic seizures following withdrawal of progesterone. Rom J Neurol Psychiatry 1994, 32: 131-3.
56. 4-subunit suppression prevents withdrawal properties of an endogenous steroid. Nature 1998, 392: 926-30.
57. 4 subunit in association with increased anxiety. J Neurosci 1998, 18: 5275-84.
58. Moran, M.H., Smith, S.S. Progesterone withdrawal 1: pro-convulsant effects. Brain Res 1998, 807: 84-90.
59. A receptor gene regulation in the brain and anxiety behavior. Steroids 2002, 67: 519-28.
60. Mattson, R.H., Cramer, J.A., Caldwell, B.V., Siconolfi, B.C. Treatment of seizures with medroxyprogesterone acetate: Preliminary report. Neurology 1984, 34: 1255-8.
61. Tsai, M.J., O'Malley, B.W. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 1994, 63: 451-86.
62. Mulac-Jericevic, B., Mullinax, R.A., DeMayo, F.J., Lydon, J.P., Conneely, O.M. Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform. Science 2000, 289: 1751-4.
63. Parsons, B., Rainbow, T.C., MacLusky, N.J., McEwen, B.S. Progestin receptor levels in rat hypothalamic and limbic nuclei. J Neurosci 1982, 2: 1446-52.
64. Mani, S.K., Allen, J.M.C., Lydon, J.P. et al. Dopamine requires the unoccupied progesterone receptor to induce sexual behavior in mice. Mol Endocrinol 1996, 10: 1728-37.
65. Clarke, C.L., Sutherland, R.L. Progestin regulation of cellular proliferation. Endocrine Rev 1990, 11: 266-300.
66. Lydon, J.P., DeMayo, F.J., Funk, C.R. et al. Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev 1995, 9: 2266-78.
67. Mani, S.K., Blaustein, J.D., O'Malley, B.W. Progesterone receptor function from a behavioral perspective. Horm Behav 1997, 31: 244-55.
68. Frye, C.A., Vongher, J.M. Progesterone and 3α,5α-THP enhance sexual receptivity in mice. Behav Neurosci 2001, 115: 1118-28.
69. Mohammad, S., Abolhassan, A., Pourgholami, M.H. Evaluation of the anticonvulsant profile of progesterone in male amygdala-kindled rats. Epilepsy Res 1998, 30: 195-202.
70. Reddy, D.S., Castaneda, D.C., O'Malley, B.W., Rogawski, M.A. Anticonvulsant activity of progesterone and neurosteroids in progesterone receptor knockout mice. J Pharmacol Exp Ther 2004, 310: 230-9.
71. Reddy, D.S., Castaneda, D.C., O'Malley, B.W., Rogawski, M.A. Seizure resistance of progesterone receptor knockout mice. FASEB J 2001, 15: A223-223.
72. Belelli, D., Bolger, M.B., Gee, K.W. Anticonvulsant profile of the progesterone metabolite 5α-pregnan-3α-ol-20-one. Eur J Pharmacol 1989, 166: 325-9.
73. Kokate, T.G., Banks, M.K., Magee, T., Yamaguchi, S., Rogawski, M.A. Finasteride, a 5α-reductase inhibitor, blocks the anticonvulsant activity of progesterone in mice. J Pharmacol Exp Ther 1999, 288: 679-84.
74. Frye, C.A., Bayon, L.E. Seizure activity is increased in endocrine states characterized by decline in endogenous levels of the neurosteroid 3α,5α-THP. Neuroendocrinology 1998, 68: 272-80.
75. Stoffel-Wagner, B. Neurosteroid metabolism in the human brain. Eur J Endocrinol 2001, 145: 669-79.
76. Reddy, D.S., Kulkarni, S.K. Development of neurosteroid-based novel psychotropic drugs. Progr Med Chem 2000, 37: 135-75.
77. Mellon, S.H., Griffin, L.D., Compagnone, N.A. Biosynthesis and action of neurosteroids. Brain Res Rev 2001, 37: 3-12.
78. Mensah-Nyagan, A.G., Do-Rego, J.L., Beaujean, D., Luu-The, V., Pelletier, G., Vaudry, H. Neurosteroids: Expression of steroidogenic enzymes and regulation of steroid biosynthesis in the central nervous system. Pharmacol Rev 1999, 51: 63-81.
79. Robel, P., Baulieu, E.E. Neurosteroids: Biosynthesis and function. Crit Rev Neurobiol 1995, 9: 383-94.
80. Corpechot, C., Young, J., Calvel, M. et al. Neurosteroids: 3α-Hydroxy-5α-pregnan-20-one and its precursors in the brain, plasma and steroidogenic glands of male and female rats. Endocrinology 1993, 133: 1003-9.
81. Frye, C.A., Rhodes, M.E., Walf, A., Harney, J. Progesterone reduces pentylenetetrazol-induced ictal activity of wild-type mice but not those deficient in type I 5α-reductase. Epilepsia 2002, 43 (Suppl 5): 14-7.
82. Herzog, A.G., Frye, C.A. Seizure exacerbation associated with inhibition of progesterone metabolism. Ann Neurol 2003, 53: 390-1.
83. Devaud, L.L., Purdy, R.H., Morrow, A.L. The neurosteroid, 3α-hydroxy-5α-pregnan-20-one, protects against bicuculline-induced seizures during ethanol withdrawal in rats. Alcohol Clin Exp Res 1995, 19: 350-5.
84. A receptors to neuroactive steroids in rats during ethanol withdrawal. J Pharmacol Exp Ther 1996, 278: 510-7.
85. Frye, C.A. The neurosteroid 3α,5α-THP has antiseizure and possible neuroprotective effects in an animal model of epilepsy. Brain Res 1995, 696: 113-20.
86. Kokate, T.G., Svensson, B.E., Rogawski, M.A. Anticonvulsant activity of neurosteroids: Correlation with γ-aminobutyric acid-evoked chloride current potentiation. J Pharmacol Exp Ther 1994, 270: 1223-9.
87. Kokate, T.G., Cohen, A.L., Karp, E., Rogawski, M.A. Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice. Neuropharmacology 1996, 35: 1049-56.
88. A receptor. J Pharmacol Exp Ther 1997, 280: 1284-95.
89. Frye, C.A., Scalise, T.J., Bayon, L.E. Finasteride blocks the reduction in ictal activity produced by exogenous estrous cyclicity. J Neuroendocrinol 1998, 10: 291-6.
90. A receptor complex for the treatment of epilepsy. Exp Opin Invest Drugs 1999, 8: 1663-71.
91. A receptor complex. J Pharmacol Exp Ther 1987, 241: 346-53.
92. Majewska, M.D., Harrison, N.L., Schwartz, R.D., Barker, J.L., Paul, S.M. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science 1986, 232: 1004-7.
93. A receptors. Prog Neurobiol 2003, 71: 67-80.
94. Gee, K.W., Bolger, M.B., Brinton, R.E., Coirini, H., McEwen, B.S. Steroid modulation of the chloride ionophore in rat brain: Structure-activity requirements, regional dependence and mechanism of action. J Pharmacol Exp Ther 1988, 246: 803-12.
95. Turner, D.M., Ransom, R.W., Yang, J.S.-J., Olsen, E.W. Steroid anesthetics and naturally occurring analogs modulate the γ-aminobutyric acid receptor complex at a site distinct from barbiturates. J Pharmacol Exp Ther 1989, 248: 960-6.
96. Rapkin, A.J., Morgan, M., Goldman, L., Brann, D.W., Simone, D., Mahesh, V.B. Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet Gyneco 1997, 190: 709-14.
97. Wang, M., Seippel, L., Purdy, R.H., Bäckström, T. Relationship between symptom severity and steroid variation in women with premenstrual syndrome: Study on serum pregnenolone, pregnenolone sulfate, 5α-pregnane-3,20-dione and 3α-hydroxy-5α-pregnan-20-one. J Clin Endocrinol Metab 1996, 81: 1076-82.
98. Genazzani, A.R., Petraglia, F., Bernardi, F., Casarosa, E., Salvestroni, C., Tonetti, A. Circulating levels of allopregnanolone in humans: Gender, age and endocrine influences. J Clin Endocrinol Metab 1998, 83: 2099-103.
99. A IPSCs during development in rat hippocampal or cerebellar slices. J Physiol 1999, 521: 437-49.
100. A receptors. Neuropharmacology. 2002, 43: 651-61.
101. Bixo, M., Andersson, A., Winblad, B., Purdy, R.H., Backstrom, T. Progesterone, 5α-pregnane-3,20-dione and 3α-hydroxy-5α- pregnane-20-one in specific regions of the human female brain in different endocrine states. Brain Res 1977, 764: 173-8.
102. Beyenburg, S., Stoffel-Wagner, B., Bauer, J. et al. Neuroactive steroids and seizure susceptibility. Epilepsy Res 2001, 44: 141-53.
103. Murri, L., Galli, R. Catamenial epilepsy, progesterone and its metabolites. Cephalalgia 1997, 20 (Suppl): 46-7.
104. A receptor expression and function during progesterone treatment and withdrawal. Mol Pharmacol 2000, 57: 1262-70.
105. 4 subunit upregulation. J Neurophysiol 2003, 89: 186-98.
106. Reddy, D.S., Kim, Y.-H., Rogawski, M.A. Neurosteroid withdrawal model of perimenstrual catamenial epilepsy. Epilepsia 2001, 42: 294-302.
107. A receptor complex in mammalian cortical neurons. J Pharmacol Exp Ther 1995, 275: 784-9.
108. A receptor plasticity during long-term exposure to and withdrawal from progesterone. Brain Res Rev 2001, 37: 81-90.
109. Reddy, D.S., Rogawski, M.A. Enhanced anticonvulsant activity of ganaxolone after neurosteroid withdrawal in a rat model of catamenial epilepsy. J Pharmacol Exp Ther 2000, 294: 909-15.
110. Reddy, D.S., Rogawski, M.A. Enhanced anticonvulsant activity of neuroactive steroids in a rat model of catamenial epilepsy. Epilepsia 2001, 42: 303-10.
111. A currents insensitive to benzodiazepine modulation in rat CA1 hippocampus. J Neurophysiol 1995, 74: 464-9.
112. File, S.E. The history of benzodiazepine dependence: A review of animal studies. Neurosci Biobehav Rev 1990, 14: 135-46.
113. Kokka, N., Sapp, D.W., Taylor, A.M., Olsen, R.W. The kindling model of alcohol dependence: Similar persistent reduction in seizure threshold to pentylenetetrazol in animals receiving chronic ethanol or chronic pentylenetetrazol. Alcoholism 1993, 17: 525-31.
114. Concas, A., Mostallino, M.C., Porcu, P. et al. Role of brain allopregnanolone in the plasticity of γ-aminobutyric acid type A receptor in rat brain during pregnancy and after delivery. Proc Natl Acad Sci USA 1998, 95: 13284-9.
115. A receptor plasticity by progesterone metabolites. Eur J Pharmacol 1999, 375: 225-35.
116. A receptor complex during pregnancy and after delivery in the rat brain. Eur J Neurosci 1998, 10: 2905-12.
117. Herzog, A.G. Psychoneuroendocrine aspects of temporolimbic epilepsy. Part II: Epilepsy and reproductive steroids. Psychosomatics 1999, 40: 102-8.
118. Bauer, J. Interactions between hormones and epilepsy in female patients. Epilepsia 2001, 42 (Suppl 3): 20-2.
119. Ross, I.P. Acetazolamide therapy in epilepsy. Lancet 1958, 2: 1308-9.
120. Lim, L.L., Foldvary, N., Mascha, E., Lee, J. Acetazolamide in women with catamenial epilepsy. Epilepsia 2001, 42: 746-9.
121. Lombroso, C.T., Forxythe, I. A long-term follow-up of acetazolamide (Diamox) in the treatment of epilepsy. Epilepsia 1960, 1: 493-500.
122. Millichap, J.G., Woodbury, D.M., Goodman, B.S. Mechanism of the anticonvulsant action of acetazolmide, a carbonic anhydrase inhibitor. J Pharmacol Exp Ther 1995, 115: 251-8.
123. Feely, M., Calvert, R., Gibson, J. Clobazam in catamenial epilepsy: A model for evaluating anticonvulsants. Lancet 1982, 2: 71-3.
124. Feely, M., Gibson, J. Intermittent clobazam for catamenial epilepsy: Tolerance avoided. J Neurol Neursurg Psychiatry 1984, 47: 1279-82.
125. Reddy, D.S., Rogawski, M.A. Chronic treatment with the neuroactive steroid ganaxolone in the rat induces anticonvulsant tolerance to diazepam but not to itself. J Pharmacol Exp Ther 2000, 295: 1241-8.
126. Zimmerman, A.W., Holder, D.T., Reiter, E.O., Dekaban, A.S. Medroxyprogesterone acetate in the treatment of seizures associated with menstruation. J Pediatr 1973, 83: 959-63.
127. Herzog, A.G. Clomiphene therapy in epileptic women with menstrual disorders. Neurology 1988, 38: 432-4.
128. Dana-Haeri, J., Richens, A. Effect of norethisterone on seizures associated with menstruation. Epilepsia 1983, 24: 377-81.
129. Haider, Y., Barnett, D.B. Catamenial epilepsy and goserelin. Lancet 1991, 338: 1530
130. Bauer, J., Wildt, L., Flugel, D., Stefan, H. The effect of a synthetic GnRH analogue on catamenial epilepsy: a study in ten patients. J Neurol 1992, 239: 284-6.
131. Tsuda, M., Suzuki, T., Misawa, M. Modulation of the decrease in the seizure threshold of pentylenetetrazole in diazepam-withdrawn mice by the neurosteroid 5α-pregnan-3α,21-diol-20-one (alloTHDOC). Addiction Biol 1997, 2: 455-60.
132. Phillipps, G.H. Structure-activity relationships in steroidal anaesthetics. J Steroid Biochem 1975, 6: 607-13.
133. Rupprecht, R., Reul, J.M., Trapp, T. et al. Progesterone receptor-mediated effects of neuroactive steroids. Neuron 1993, 11: 523-30.
134. A receptor. J Med Chem 1997, 40: 61-72.
135. A receptor complex: The pharmacological properties and therapeutic potential of epalons. Crit Rev Neurobiol 1995, 9: 207-27.
136. Reddy, D.S., Woodward, R. Ganaxoloe: A perspective overview. Drugs Fut 2004, 29: 227-42.
137. Gasior, M., Carter, R.B., Goldberg, S.R., Witkin, J.M. Anticonvulsant and behavioral effects of neuroactive steroids alone and in conjunction with diazepam. J Pharmacol Exp Ther 1997, 282: 543-53.
138. Gasior, M., Ungard, J.T., Beekman, M., Carter, R.B., Witkin, J.M. Acute and chronic effects of the synthetic neuroactive steroid, ganaxolone, against the convulsive and lethal effects of pentylenetrazol in seizure-kindled mice: Comparison with diazepam and valproate. Neuropharmacology 2000, 39: 1184-96.
139. Kokate, T.G., Yamaguchi, S., Pannel, L.K. et al. Lack of anticonvulsant tolerance to the neuroactive steroid pregnanolone in mice. J Pharmacol Exp Ther 1998, 287: 553-8.
140. Ramsey, M.A.E., Savege, T.M., Simpson, B.R.J., Goodwin, R. Controlled sedation with alphaxolone-alphadalone. Br Med J 1974, 2: 256-659.
141. Wieland, S., Belluzzi, J., Hawkinson, J.E. et al. Anxiolytic and anticonvulsant activity of a synthetic neuroactive steroid Co 3-0593. Psychopharmacology 1997, 134: 46-54.
142. Czlonkowska, A.I., Krzascik, P., Sienkiewicz-Jarosz, H. et al. Tolerance to the anticonvulsant activity of midazolam and allopregnanolone in a model of picrotoxin seizures. Eur J Pharmacol 2001, 425: 121-7.
143. Marshall, F.H., Stratton, S.C., Mullings, J. et al. Development of tolerance in mice to the sedative effects of the neuroactive steroid minaxolone following chronic exposure. Pharmacol Biochem Behav 1997, 58: 1-8.
144. Palmer, A.A., Moyer, M.R., Crabbe, J.C., Phillips, T.J. Initial sensitivity, tolerance and cross-tolerance to allopregnanolone- and ethanol-induced hypothermia in selected mouse lines. Psychopharmacology 2002, 162: 313-22.
145. Haigh, J.R.M., Feely, M. Tolerance to the anticonvulsant effect of benzodiazepines. Trends Pharmacol Sci 1988, 9: 361-6.
146. Löscher, W., Rundfeldt, C., Honack, D., Ebert, U. Long-term studies on anticonvulsant tolerance and withdrawal characteristics of benzodiazepine receptor ligands in different seizure models in mice. I. Comparison of diazepam, clonazepam, clobazam and abecarnil. J Pharmacol Exp Ther 1996, 279: 561-72.
147. Bicikova, M., Dibbelt, L., Hill, M., Hampl, R., Starka, L. Allopregnanolone in women with premenstrual syndrome. Horm Metab Res 1998, 30: 227-30.
148. Monteleone, P., Luisi, S., Tonetti, A. et al. Allopregnanolone concentrations and premenstrual syndrome. Eur J Endocrinol 2000, 142: 269-73.
149. Purdy, R.H., Morrow, A.L., Moore, P.H. Jr., Paul, S.M. Stress-induced elevations of gamma-aminobutyric acid type A receptor-active steroids in the rat brain. Proc Natl Acad Sci USA 1991, 88: 4553-7.
150. Sundstrom, I., Nyberg, S., Bäckström, T. Patients with premenstrual syndrome have reduced sensitivity to midazolam compared to control subjects. Neuropsychopharmacology 1997, 17: 370-81.
151. Monaghan, E.P., Navalta, L.A., Shum, L., Ashbrock, D.W., Lee, D.A. Initial human experience with ganaxolone, a neuroactive steroid with antiepileptic activity. Epilepsia 1997, 38: 1026-31.
152. Laxer, K., Blum, D., Abou-Khalil, B.W. et al. Assessment of ganaxolone's anticonvulsant activity using a randomized, double-blind, presurgical trial design. Ganaxolone Presurgical Study Group. Epilepsia 2000, 41: 1187-94.
153. Kerrigan, J.F., Shields, W.D., Nelson, T.Y. et al. Ganaxolone for treating intractable infantile spasms: A multicenter, open-label, add-on trial. Epilepsy Res. 2000, 42: 133-9.
154. Vanover, K.E., Edgar, D.M., Seidel, W.F. et al. Response-rate suppression in operant paradigm as predictor of soporific potency in rats and identification of three novel sedative-hypnotic neuroactive steroids. J Pharmacol Exp Ther 1999, 291: 1317-23.
155. A receptors. J Pharmacol Exp Ther 2000, 295: 337-45.
156. McAuley, J.W., Moore, J.L., Reeves, A.L., Flyak, J., Monaghan, E.P., Data, J. A pilot study of the neurosteroid ganaxolone in catamenial epilepsy: Clinical experience in two patients. Epilepsia 2001, 42: 85 (Abstract).